Peanut (arachis hypogaea) allergen powder-dnfp - Biologic Drug Details

Summary for peanut (arachis hypogaea) allergen powder-dnfp

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for peanut (arachis hypogaea) allergen powder-dnfp Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for peanut (arachis hypogaea) allergen powder-dnfp Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for peanut (arachis hypogaea) allergen powder-dnfp Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory of Peanut Allergen Powder-DNFP

Last updated: February 20, 2026

What is the current market landscape for peanut allergen powder-DNFP?

Peanut allergen powder-dnfp (Palforzia) by Nestlé and Aimmune Therapeutics, approved by the FDA in January 2020, targets peanut allergy immunotherapy. The global allergen immunotherapy market was valued at approximately $5.4 billion in 2021, with peptide and protein-derived formulations constituting a significant segment. Palforzia's inclusion in this market marked a milestone in treating food allergies.

How does regulatory approval influence market penetration?

FDA approval facilitates prescriber confidence and insurance reimbursement. Palforzia received approval for ages 4-17. Additional regulatory clearance in the European Union and Japan is ongoing or under consideration. Market launch began in 2020, with commercial availability expanding gradually. As of 2022, sales in the United States approached $200 million, with expectations for continued growth.

What are the key drivers of market growth?

Demand for effective peanut allergy treatments rises as prevalence increases, especially among children. The CDC reports peanut allergy prevalence at 1.2% of U.S. children, up from 0.4% in 1997. Greater awareness, diagnosis, and treatment options expand the market. Pricing ranges from $4,000 to $15,000 annually per patient, depending on dosing schedules and insurance coverage, thus generating substantial revenue potential.

What barriers could impact the financial trajectory?

Limited patient population constrains total addressable market. The strict administration protocols, potential adverse reactions, and high treatment costs may hinder adoption. Reimbursement policies vary across regions. Long-term efficacy data remains under review, which could influence physician prescribing behavior.

How does competitive landscape shape financial prospects?

Currently, Palforzia dominates peanut allergy immunotherapy. Emerging treatments include biologics like Dupixent (dupilumab) and other oral immunotherapies under clinical development. These alternatives could erode market share if they demonstrate superior efficacy or safety.

What are projected financial outcomes over the next five years?

Analysts estimate U.S. sales could surpass $600 million by 2025, driven by increased awareness, expanded indications (e.g., adults), and new formulations. Globally, market penetration depends on regulatory approvals and healthcare infrastructure. Pricing strategies are under pressure to balance profitability with patient affordability.

How do manufacturing and supply chain factors influence financial stability?

Production capacity expansion occurs via contract manufacturing organizations (CMOs). Raw material costs, quality control, and scalability impact margins. The complexity of allergen powder manufacturing necessitates strict quality assurance, which increases operational costs.

Summary table: Key metrics for peanut allergen powder-DNFP

Metric	Data	Source
FDA approval	January 2020	[1]
US sales (2022)	Approx. $200 million	Company reports
Estimated U.S. market size	600,000–800,000 children (aged 4–17)	CDC
Price range per patient/year	$4,000–$15,000	Market surveys
Projected 2025 U.S. sales	>$600 million	Analyst estimates
Global approvals	Pending in EU, Japan	Regulatory agencies

Key takeaways

• Palforzia holds dominant position but faces competition from biologics and oral immunotherapies.
• Regulatory approvals and payer coverage are critical to growth.
• High treatment costs and reimbursement variability limit market penetration.
• Long-term efficacy data and expanded indications will influence future sales.
• Manufacturing scalability affects margins and supply stability.

FAQs

1. What is the primary revenue source for peanut allergen powder-dnfp?
Prescription sales within the U.S. drive revenue, with international markets emerging as approvals expand.

2. How does insurance coverage impact sales?
Reimbursement policies significantly influence patient access, affecting overall sales volume.

3. Are there current competitors to Palforzia?
No direct FDA-approved oral immunotherapy is currently marketed; however, biologics and ongoing clinical trials may change this landscape.

4. What regions are expected to be growth drivers?
The U.S. remains dominant; European and Asian markets are key countries for future expansion.

5. How does treatment adherence influence the financial outlook?
High adherence rates are necessary for optimal outcomes; poor adherence diminishes treatment value and sales.

---

References

[1] U.S. Food and Drug Administration. (2020). FDA approves first drug for treatment of peanut allergy. Retrieved from https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treatment-peanut-allergy